4.5 Article

Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration

期刊

VACCINE
卷 34, 期 36, 页码 4313-4320

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2016.06.075

关键词

Streptococcus pneumoniae; Pneumococcal conjugate vaccine; Nasopharyngeal colonization; Antibody concentrations; Indirect protection; Modeling

资金

  1. Pfizer

向作者/读者索取更多资源

Background: A prior 7- and 13-valent pneumococcal conjugate vaccine (PCV7 and PCV13) study provided sufficient data (N =1754; Jewish, n = 1154; Bedouin, n = 595; other, n = 5) to investigate the association between nasopharyngeal (NP) acquisition of common PCV7 serotypes and cross-reacting 6A (PCV7 + 6A) and IgG concentrations. Methods: Using a logistic regression model, serotype specific association between postinfant series IgG concentration (age 7 months) and new NP acquisition between ages 7 and 24 months was assessed and adjusted for ethnicity. From a subset of subjects with new NP acquisition (n = 9-152 across serotypes studied), new acquisition percentiles and associated IgG concentrations were calculated. Results: For the serotypes studied, new NP acquisition rates decreased as IgG concentrations increased. Ethnicity did not influence these associations despite differences in carriage rates. From the subset with new acquisitions, 50% of the events occurred at IgG concentrations >0.61-5.58 mu g/mL; and 10% of the acquisitions occurred at IgG concentrations >2.48-17.69 mu g/mL. Conclusion: Remarkably high IgG concentrations are required to reduce NP acquisition. These IgG concentrations differ between serotypes. Ethnicity did not influence the association between high IgG concentrations and prevention of carriage despite differences in carriage rates. Since carriage determines transmission, these results may have important implications for herd protection. (C) 2016 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

A Prospective, Population-based Study to Determine the Incidence and Bacteriology of Bacterial Conjunctivitis in Children <2 Years of Age Following 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Sequential Implementation

Ron Dagan, Shalom Ben-Shimol, David Greenberg, Noga Givon-Lavi

Summary: This study examined the impact of pneumococcal conjugate vaccines (PCVs) on bacterial conjunctivitis incidence in children aged 2-23 months in southern Israel. The implementation of PCV13 resulted in a significant decline in disease caused by PCV13 serotypes without significant replacement by non-PCV13 serotypes. The findings suggest a marked reduction in overall conjunctivitis rates in children under 2 years of age.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

Serotype Patterns of Pneumococcal Disease in Adults Are Correlated With Carriage Patterns in Older Children

Anne L. Wyllie, Joshua L. Warren, Gili Regev-Yochay, Noga Givon-Lavi, Ron Dagan, Daniel M. Weinberger

Summary: The frequency of serotypes causing IPD differs between adults and children, as well as between older and younger adults and adults with and without comorbidities. Older children, rather than infants, were found to have a better correlation with the serotype-specific IPD patterns in adults, indicating they may play a more influential role in disease patterns. These findings could help optimize vaccination strategies to reduce disease burden across different age groups.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

Effectiveness of Pneumococcal Conjugate Vaccines Against Community-acquired Alveolar Pneumonia Attributable to Vaccine-serotype Streptococcus pneumoniae Among Children

Joseph A. Lewnard, Noga Givon-Lavi, Ron Dagan

Summary: The study analyzed the effectiveness of PCV in protecting children against pneumonia caused by different vaccine-targeted pneumococcal serotypes in southern Israel. The results showed that PCV could effectively reduce carriage of vaccine-serotype pneumococci and decrease the risk of disease progression.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

A Nationwide Outbreak of Invasive Pneumococcal Disease in Israel Caused by Streptococcus pneumoniae Serotype 2

Ron Dagan, Shalom Ben-Shimol, Rachel Benisty, Gili Regev-Yochay, Stephanie W. Lo, Stephen D. Bentley, Paulina A. Hawkins, Lesley McGee, Merav Ron, Noga Givon-Lavi, Lea Valinsky, Assaf Rokney

Summary: In Israel during the PCV13 era, an outbreak of Sp2 IPD caused by the emerging ST-13578 clone was identified. This clone, mainly found in the Jewish population and specific regions of Israel, showed clonality and likely evolved from ST-1504 through recombination processes.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

Effectiveness of the 7-and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media

Ron Dagan, Bart Adriaan van der Beek, Shalom Ben-Shimol, Tamara Pilishvili, Noga Givon-Lavi

Summary: The study demonstrates that the 7-valent and 13-valent pneumococcal vaccines are effective in protecting against otitis media caused by specific serotypes, especially serotypes 19F and 19A.

CLINICAL INFECTIOUS DISEASES (2021)

Article Microbiology

Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project

Maria Deloria Knoll, Julia C. Bennett, Maria Garcia Quesada, Eunice W. Kagucia, Meagan E. Peterson, Daniel R. Feikin, Adam L. Cohen, Marissa K. Hetrich, Yangyupei Yang, Jenna N. Sinkevitch, Krow Ampofo, Laurie Aukes, Sabrina Bacci, Godfrey Bigogo, Maria-Cristina C. Brandileone, Michael G. Bruce, Romina Camilli, Jesus Castilla, Guanhao Chan, Grettel Chanto Chacon, Pilar Ciruela, Heather Cook, Mary Corcoran, Ron Dagan, Kostas Danis, Sara de Miguel, Philippe De Wals, Stefanie Desmet, Yvonne Galloway, Theano Georgakopoulou, Laura L. Hammitt, Markus Hilty, Pak-Leung Ho, Sanjay Jayasinghe, James D. Kellner, Jackie Kleynhans, Mirjam J. Knot, Jana Kozakova, Karl Gustaf Kristinsson, Shamez N. Ladhani, Claudia S. Lara, Maria Eugenia Leon, Tiia Lepp, Grant A. Mackenzie, Lucia Mad'arova, Allison McGeer, Tuya Mungun, Jason M. Mwenda, J. Pekka Nuorti, Nehemie Nzoyikorera, Lucia Helena De Oliveira, Metka Paragi, Tamara Pilishvili, Rodrigo Puentes, Eric Rafai, Samir K. Saha, Larisa Savrasova, Camelia Savulescu, J. Anthony Scott, Kevin J. Scott, Fatima Serhan, Lena Petrova Setchanova, Nadja Sinkovec Zorko, Anna Skoczynska, Todd D. Swarthout, Palle Valentiner-Branth, Mark van Der Linden, Didrik E. Vestrheim, Anne von Gottberg, Inci Yildirim, Kyla Hayford

Summary: This study provides a comprehensive overview of serotype-specific IPD surveillance in countries using PCV10/13, with a focus on the PSERENADE project. The analysis includes data from multiple sites across geographic regions and different vaccination schedules, aiming to estimate the impact of PCV and inform decision-making at national and global levels.

MICROORGANISMS (2021)

Article Microbiology

Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project

Maria Garcia Quesada, Yangyupei Yang, Julia C. Bennett, Kyla Hayford, Scott L. Zeger, Daniel R. Feikin, Meagan E. Peterson, Adam L. Cohen, Samanta C. G. Almeida, Krow Ampofo, Michelle Ang, Naor Bar-Zeev, Michael G. Bruce, Romina Camilli, Grettel Chanto Chacon, Pilar Ciruela, Cheryl Cohen, Mary Corcoran, Ron Dagan, Philippe De Wals, Stefanie Desmet, Idrissa Diawara, Ryan Gierke, Marcela Guevara, Laura L. Hammitt, Markus Hilty, Pak-Leung Ho, Sanjay Jayasinghe, Jackie Kleynhans, Karl G. Kristinsson, Shamez N. Ladhani, Allison McGeer, Jason M. Mwenda, J. Pekka Nuorti, Kazunori Oishi, Leah J. Ricketson, Juan Carlos Sanz, Larisa Savrasova, Lena Petrova Setchanova, Andrew Smith, Palle Valentiner-Branth, Maria Teresa Valenzuela, Mark van der Linden, Nina M. van Sorge, Emmanuelle Varon, Brita A. Winje, Inci Yildirim, Jonathan Zintgraff, Maria Deloria Knoll

Summary: Introduction of PCV has reduced pneumococcal meningitis incidence, with remaining cases showing different serotype distribution in countries using PCV10/13 for at least 5-7 years. Higher-valency PCVs may target over half of remaining cases, but further data is needed for generalizability in the African meningitis belt.

MICROORGANISMS (2021)

Article Immunology

Unraveling the Impact of Pneumococcal Conjugate Vaccines on Ambulatory Antibiotic Drug Consumption in Young Children: An Interrupted Time-Series Analysis

Dana Danino, Bart Adriaan van der Beek, Noga Givon-Lavi, David Greenberg, Shalom Ben-Shimol, Ron Dagan

Summary: Following the implementation of pneumococcal conjugate vaccines, the prescription rate of antibiotics for children under 5 years of age decreased significantly within a short period of time and stabilized within 5 years, mainly driven by drugs like amoxicillin. Children under 2 years of age and Bedouin ethnicity had higher antibiotic prescription rates before PCV implementation, but saw a faster decline post-PCV, nearly eliminating the gaps between different age groups and ethnicities.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance

Shalom Ben-Shimol, Gili Regev-Yochay, Noga Givon-Lavi, Bart Adriaan van der Beek, Tal Brosh-Nissimov, Avi Peretz, Orli Megged, Ron Dagan

Summary: A ten-year surveillance after the implementation of PCV7/PCV13 showed a significant reduction in invasive pneumococcal disease in children and adults, with stabilization after four years. The main PCV13 serotypes were 3, 19A, and 14, while serotypes 8 and 12F were the predominant nonvaccine serotypes.

CLINICAL INFECTIOUS DISEASES (2022)

Correction Immunology

Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media (vol 73, pg 650, 2022)

Ron Dagan, Bart Adriaan van der Beek, Shalom Ben-Shimol, Tamara Pilishvili, Noga Givon-Lavi

CLINICAL INFECTIOUS DISEASES (2022)

Article Immunology

The impact of the pneumococcal conjugate vaccines on the incidence of community-acquired alveolar pneumonia in premature compared with in term-born infants

Yaniv Faingelernt, Ron Dagan, Noga Givon-Lavi, Bart Adriaan van der Beek, Shalom Ben-Shimol, Eilon Shany, David Greenberg

Summary: The implementation of PCV vaccination in Israel has led to a reduction in CAAP incidence in both preterm-born and term-born infants. The reduction rate was higher in outpatients compared to hospitalized children, and the disparity in CAAP rates between preterm-born and term-born infants was also reduced.

VACCINE (2022)

Article Immunology

International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease

R. A. Gladstone, L. Siira, O. B. Brynildsrud, D. F. Vestrheim, P. Turner, S. C. Clarke, S. Srifuengfung, R. Ford, D. Lehmann, E. Egorova, E. Voropaeva, G. Haraldsson, K. G. Kristinsson, L. McGee, R. F. Breiman, S. D. Bentley, C. L. Sheppard, N. K. Fry, J. Corander, M. Toropainen, A. Steens

Summary: This study used genomics to investigate the international links between outbreaks of vaccine preventable serotype 4 sequence type 801 in shipyards in several countries. The findings suggest that the total diversity of ST801 within the outbreaks cannot be solely explained by recent transmission alone, indicating potential international transmission between shipyards.

VACCINE (2022)

Article Pediatrics

Disproportionate reduction in respiratory vs. non-respiratory outpatient clinic visits and antibiotic use in children during the COVID-19 pandemic

Noga Givon-Lavi, Dana Danino, Bart Adriaan van der Beek, Amir Sharf, David Greenberg, Shalom Ben-Shimol

Summary: The COVID-19 pandemic resulted in a significant reduction in pediatric outpatient clinic visits and prescriptions, especially for respiratory conditions.

BMC PEDIATRICS (2022)

Article Psychiatry

COVID-19 Booster Vaccination Among Individuals With Schizophrenia in Israel

Dana Tzur Bitan, Khalaf Kridin, Noga Givon-Lavi, Israel Krieger, Ehud Kaliner, Arnon Dov Cohen, Orly Weinstein

Summary: This study found lower rates of COVID-19 vaccination among individuals with schizophrenia, especially during the booster vaccine phase. These gaps persisted even after adjusting for demographic and clinical variables. Countries worldwide should adopt strategies to reduce vaccination gaps and improve healthcare for this high-risk population.

JAMA PSYCHIATRY (2022)

Editorial Material Psychiatry

Severe breakthrough COVID-19 infections in vaccinated patients with schizophrenia in Israel

Dana Tzur Bitan, Noga Givon-Lavi, Khalaf Kridin, Ehud Kaliner, Israel Krieger, Arnon Dov Cohen, Orly Weinstein

WORLD PSYCHIATRY (2022)

暂无数据